What is Citryll?
Citryll is at the forefront of developing novel therapeutic strategies for immune-mediated inflammatory diseases. The company's innovative approach centers on targeting NETs, a fundamental component of inflammation that has historically been unaddressed. By intervening at this core inflammatory driver, Citryll aims to move beyond conventional pathway management and symptom alleviation, offering a more fundamental solution to reduce inflammatory drive. This focus positions Citryll to address a critical unmet need in the treatment of various inflammatory conditions.
How much funding has Citryll raised?
Citryll has raised a total of $127.9M across 3 funding rounds:
Series A
$17.2M
Series B
$20.8M
Series B
$89.9M
Series A (2019): $17.2M with participation from BrightGene, ModiQuest B.V., BOM Brabant Ventures, and Curie Capital
Series B (2020): $20.8M led by BrightGene, Seventure Partners, ModiQuest B.V., BOM Brabant Ventures, and BGV (BioGeneration Ventures
Series B (2024): $89.9M supported by Curie Capital, Forbion, Novartis, and Johnson & Johnson Innovation
Key Investors in Citryll
BGV (BioGeneration Ventures
BioGeneration Ventures is a venture capital firm specializing in seed investments for innovative early-stage life science companies, particularly in Europe. They act as lead investors and offer expertise and support to accelerate product development for companies addressing high unmet medical needs in the biotech sector.
Forbion
Forbion is a global life sciences venture capital firm headquartered in Naarden, the Netherlands, with additional offices in Munich, Germany, and Boston, USA. They invest across multiple fund strategies covering all stages of pharmaceutical drug development, with a primary focus on innovative therapeutics companies in Europe and North America.
Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide.
What's next for Citryll?
With substantial enterprise-level and strategic investment backing, Citryll is poised for accelerated growth and the advancement of its pipeline. The recent major strategic investment, particularly from prominent players in the life sciences sector, signals strong confidence in Citryll's technology and its potential for market impact. This capital infusion will likely fuel further research and development, clinical trial progression, and potential commercialization efforts, solidifying Citryll's position as a key innovator in the inflammatory disease therapeutics space.
See full Citryll company page
